Figures computed from official regulatory filings — .
Analysttarget 5.92 USD (+153%) · consensus 5/5 · 10 buy · 0 hold · 0 sell
Ownershipinsiders 6.72% · institutions 80.43% · short 12.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Ovid Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
9 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Carter Charles Ross | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Greka Anna | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Friedman Bart | Award | $22.5K | SEC |
| Fitzgerald Kevin Joseph | Award | $45K | SEC |
| PAPADOPOULOS STELIOStrack record | Award | $45K | SEC |
| LEVIN JEREMY Mtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LEVIN JEREMY Mtrack record | Exercise | $66.3K | SEC |
| Fitzgerald Kevin Joseph | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PAPADOPOULOS STELIOStrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Friedman Bart | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ALEXANDER MARGARET A. | Sell | $16.9K | SEC |
| Rona Jeffrey A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LEVIN JEREMY Mtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rona Jeffrey A | Sell | $12.4K | SEC |
| Rona Jeffrey A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bernstein Karen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ALEXANDER MARGARET A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Duncan Barbara Gayle | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ALEXANDER MARGARET A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LEVIN JEREMY Mtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LEVIN JEREMY Mtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| LEVIN JEREMY Mtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| LEVIN JEREMY Mtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| LEVIN JEREMY Mtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| Takeda Pharmaceuticals U.S.A., Inc. | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |